Literature DB >> 15328567

Fatal propofol infusion syndrome in association with ketogenic diet.

F A M Baumeister1, R Oberhoffer, G M Liebhaber, J Kunkel, J Eberhardt, H Holthausen, J Peters.   

Abstract

Propofol is used for the treatment of refractory status epilepticus. When given as a long-term infusion propofol may cause a rare but frequently fatal complication, the propofol infusion syndrome. The hallmarks are metabolic acidosis, lipemia, rhabdomyolysis and myocardial failure. Propofol infusion syndrome is caused by impaired fatty acid oxidation. Beside anticonvulsants the ketogenic diet, a high-fat, low-carbohydrate, adequate-protein diet, is an effective treatment for difficult-to-control seizures. We report a 10-year-old boy with catastrophic epilepsy, who developed fatal propofol infusion syndrome when a ketogenic diet was initiated. Substances like propofol which impair fatty acid oxidation may pose an increased risk if combined with ketogenic diet.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328567     DOI: 10.1055/s-2004-820992

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  20 in total

1.  Treatment of refractory status epilepticus in childhood.

Authors:  John M Schreiber; William D Gaillard
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

2.  Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus.

Authors:  Mackenzie C Cervenka; Sara Hocker; Matthew Koenig; Barak Bar; Bobbie Henry-Barron; Eric H Kossoff; Adam L Hartman; John C Probasco; David R Benavides; Arun Venkatesan; Eliza C Hagen; Denise Dittrich; Tracy Stern; Batya Radzik; Marie Depew; Filissa M Caserta; Paul Nyquist; Peter W Kaplan; Romergryko G Geocadin
Journal:  Neurology       Date:  2017-02-08       Impact factor: 9.910

3.  A Practical Approach to Ketogenic Diet in the Pediatric Intensive Care Unit for Super-Refractory Status Epilepticus.

Authors:  Raquel Farias-Moeller; Luca Bartolini; Archana Pasupuleti; R D Brittany Cines; Amy Kao; Jessica L Carpenter
Journal:  Neurocrit Care       Date:  2017-04       Impact factor: 3.210

4.  The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit.

Authors:  Mackenzie C Cervenka; Adam L Hartman; Arun Venkatesan; Romergryko G Geocadin; Eric H Kossoff
Journal:  Neurocrit Care       Date:  2011-12       Impact factor: 3.210

Review 5.  Practical Considerations for Ketogenic Diet in Adults With Super-Refractory Status Epilepticus.

Authors:  Neha Kaul; Joshua Laing; John-Paul Nicolo; Judy Nation; Patrick Kwan; Terence J O'Brien
Journal:  Neurol Clin Pract       Date:  2021-10

Review 6.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 7.  Survey of Pharmacists Regarding the Use of Propofol Infusions in the PICUs in North America.

Authors:  Kenneth J Kurek; Aaron A Harthan; Sandeep Tripathi
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Nov-Dec

Review 8.  Systemic Complications Following Status Epilepticus.

Authors:  Maximiliano A Hawkes; Sara E Hocker
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-07       Impact factor: 5.081

9.  Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study.

Authors:  Russel J Roberts; Jeffrey F Barletta; Jeffrey J Fong; Greg Schumaker; Philip J Kuper; Stella Papadopoulos; Dinesh Yogaratnam; Elise Kendall; Renee Xamplas; Anthony T Gerlach; Paul M Szumita; Kevin E Anger; Paul A Arpino; Stacey A Voils; Philip Grgurich; Robin Ruthazer; John W Devlin
Journal:  Crit Care       Date:  2009-10-29       Impact factor: 9.097

10.  Ketogenic Diet in the Treatment of Super-Refractory Status Epilepticus at a Pediatric Intensive Care Unit: A Single-Center Experience.

Authors:  Markus Breu; Chiara Häfele; Sarah Glatter; Petra Trimmel-Schwahofer; Johann Golej; Christoph Male; Martha Feucht; Anastasia Dressler
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.